PMID- 34268872 OWN - NLM STAT- MEDLINE DCOM- 20220128 LR - 20220128 IS - 1759-7714 (Electronic) IS - 1759-7706 (Print) IS - 1759-7706 (Linking) VI - 12 IP - 17 DP - 2021 Sep TI - Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). PG - 2360-2368 LID - 10.1111/1759-7714.14078 [doi] AB - BACKGROUND: Previous studies have demonstrated that PD-1 inhibitors are effective in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). However, whether the combination of PD-1 inhibitors and antiangiogenic agents benefit advanced NSCLC patients as subsequent therapy remains unknown. In this study, we retrospectively reviewed the efficacy and safety profile of this combination strategy as subsequent therapy for NSCLC patients in a real-world setting. METHODS: A total of 30 patients with advanced NSCLC, who progressed after at least two cycles of platinum-based chemotherapy or targeted therapy and subsequently received combination therapy with a PD-1 inhibitor and antiangiogenic agent, were included in this study. The safety profile and efficacy were also investigated. RESULTS: At the time of a median follow-up period of 10.7 months, 28 patients had experienced progression of disease and 16 patients had died. The median progression-free survial (mPFS) was 5.0 months (95% confidence interval [CI]: 3.179-6.821), and the median overall survival (mOS) was 14.3 months (95% CI: 8.912-19.659). The objective response rate (ORR) and the disease control rate (DCR) were 10.3% and 72.4%, respectively (0 complete remission, three partial responses and 18 stable disease in 29 patients with measurable lesions). Patients with PD-L1 expression of at least 1% of tumor cells (n = 5) had relatively longer mPFS compared to those with PD-L1-negative tumors (n = 14), (11.6 months vs. 3.7 months). Treatment was suspended in two patients due to grade 3 immune-related pneumonia and pancreatitis, respectively. No novel adverse events (AEs) or grade 4 AEs were observed. CONCLUSIONS: A combination of PD-1 inhibitors and antiangiogenic targeting agents may be beneficial for patients with advanced or metastatic NSCLC as subsequent treatment, especially for patients with PD-L1 protein expression positive, and treatment is well tolerated. CI - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. FAU - Xu, Ziyi AU - Xu Z AUID- ORCID: 0000-0002-5747-5707 AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Teng AU - Li T AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Hu, Xingsheng AU - Hu X AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Hao, Xuezhi AU - Hao X AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Xing, Puyuan AU - Xing P AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Junling AU - Li J AUID- ORCID: 0000-0002-7361-325X AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article DEP - 20210716 PL - Singapore TA - Thorac Cancer JT - Thoracic cancer JID - 101531441 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Adult MH - Aged MH - Angiogenesis Inhibitors/*therapeutic use MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology MH - Drug Therapy, Combination MH - Female MH - Humans MH - Immune Checkpoint Inhibitors/*therapeutic use MH - Lung Neoplasms/*drug therapy/pathology MH - Male MH - Middle Aged MH - Retrospective Studies PMC - PMC8410518 OTO - NOTNLM OT - advanced or metastatic non-small-cell lung cancer (NSCLC) OT - antiangiogenic targeting agents OT - combination therapy OT - programmed cell death-1 (PD-1) inhibitors OT - subsequent therapy COIS- All authors declare that they have no conflicts of interest that might be relevant to the content of this manuscript. The abstract of this paper was presented at the IASLC 2020 World Conference on Lung Cancer as a poster presentation with interim findings. The poster's abstract was published in "Poster Abstracts" in Journal of Thoracic Oncology: DOI:https://doi.org/10.1016/j.jtho.2021.01.1199. EDAT- 2021/07/17 06:00 MHDA- 2022/01/29 06:00 PMCR- 2021/09/01 CRDT- 2021/07/16 06:59 PHST- 2021/06/24 00:00 [revised] PHST- 2021/06/06 00:00 [received] PHST- 2021/06/26 00:00 [accepted] PHST- 2021/07/17 06:00 [pubmed] PHST- 2022/01/29 06:00 [medline] PHST- 2021/07/16 06:59 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - TCA14078 [pii] AID - 10.1111/1759-7714.14078 [doi] PST - ppublish SO - Thorac Cancer. 2021 Sep;12(17):2360-2368. doi: 10.1111/1759-7714.14078. Epub 2021 Jul 16.